LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Home・Akcijų sąrašas・Compugen Ltd

Compugen Ltd

Atidarymo kaina

2.68 -3.94

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.66

Max

2.79

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-65M -7.7M
Pardavimai	-65M 2.2M
P/E Sektoriaus vid.	7.368 50.102
Pelnas, tenkantis vienai akcijai	-0.08
Pelno marža	-352.436
Darbuotojai	75
EBITDA	-64M -7.7M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+72.1% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-5.6M 265M
Ankstesnė atidarymo kaina	6.62
Ankstesnė uždarymo kaina	2.68

Compugen Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-28 22:47; UTC

Uždarbis

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

2026-05-28 20:45; UTC

Uždarbis

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

2026-05-28 23:43; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

2026-05-28 23:39; UTC

Rinkos pokalbiai

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

2026-05-28 23:31; UTC

Rinkos pokalbiai

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

2026-05-28 23:17; UTC

Rinkos pokalbiai

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

2026-05-28 23:02; UTC

Rinkos pokalbiai

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

2026-05-28 22:41; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-28 22:41; UTC

Rinkos pokalbiai

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

2026-05-28 22:37; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

M&A-Related Insurance Payments In North America Rise -- Market Talk

2026-05-28 22:04; UTC

Įsigijimai, susijungimai, perėmimai

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

2026-05-28 22:04; UTC

Įsigijimai, susijungimai, perėmimai

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

2026-05-28 21:12; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

2026-05-28 21:00; UTC

Uždarbis

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

2026-05-28 20:57; UTC

Uždarbis

Dell Stock Soars on Blowout Earnings -- Barrons.com

2026-05-28 20:55; UTC

Uždarbis

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

2026-05-28 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-28 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-28 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-28 20:48; UTC

Karštos akcijos

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

2026-05-28 20:34; UTC

Uždarbis

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

2026-05-28 20:31; UTC

Uždarbis

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

2026-05-28 20:28; UTC

Uždarbis

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

2026-05-28 20:26; UTC

Uždarbis

Dell Stock Soars on Blowout Earnings -- Barrons.com

2026-05-28 20:20; UTC

Uždarbis

Costco 3Q Membership Fees $1.37B

2026-05-28 20:20; UTC

Uždarbis

Costco 3Q Net Sales $69.15B

2026-05-28 20:19; UTC

Uždarbis

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

2026-05-28 20:19; UTC

Uždarbis

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

2026-05-28 20:17; UTC

Uždarbis

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

2026-05-28 20:17; UTC

Uždarbis

Costco 3Q Same-Store Sales Up 9.8% >COST

Akcijų palyginimas

Kainos pokytis

Compugen Ltd Prognozė

Kainos tikslas

By TipRanks

72.1% į viršų

12 mėnesių prognozė

Vidutinis 4.75 USD 72.1%

Aukščiausias 6 USD

Žemiausias 4 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Compugen Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Compugen Ltd akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.